Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors leverage to suppress the immune system by reshaping the tumor microenvironment to resist treatment. A combined targeted therapy approach improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.